Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript

Jul 21, 2022 / NTS GMT
Release Date Price: $0.72634
Unidentified Participant

Thank you for standing by, and welcome to the Paradigm Biopharmaceuticals investor webinar, today. All participants are in a listen-only mode. There will be an initial slide presentation lasting approximately 40 minutes before we allow some time to get through as much Q&A as possible. (Operator Instructions) [If you are here] on behalf of Paradigm today, we have Chairman, Paul Rennie; CEO, Marco Polizzi; Chief Medical Officer, Dr. Donna Skerrett; and Director of Investor Relations, Simon White. To begin, I'll hand it over to Simon. Please go ahead.

Simon White
Paradigm Biopharmaceuticals Ltd. - Director of Investor Relations

Thanks, Matt. And a big welcome and thank you to everyone who has dialed into today's investor update. Today's webinar is an opportunity for Paradigm to introduce a new CEO, Marco Polizzi, who officially joins the company on July 1. Marco will provide some detail on his background in the industry and what excites him with the opportunity in front of us at Paradigm. We will then hear from Dr. Donna Skerrett on the progress

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot